CHAI selects Mylan subsidiary to provide HIV/AIDS treatment

PITTSBURGH The Clinton HIV/AIDS Initiative has selected a generic drug maker as its supplier of five antiretroviral drugs used in second-line treatment regimens under its UNITAID-funded projects in the developing world.

Mylan announced Monday that CHAI had selected India-based subsidiary Matrix Labs to supply the five drugs, which the company did not specify, as well as seven antiretroviral drugs used to treat children. Mylan owns 71.2% of Matrix.

“Facilitating patient access to affordable, quality treatments has helped transform AIDS from a fatal illness into a manageable chronic condition,” Mylan vice chairman and CEO Robert Coury stated. “Ensuring that access to these treatments continues to expand is a critical piece of solving this crisis.”